HUTCHMED (HCM) schedules 2025 final results release and investor calls
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
HUTCHMED (China) Limited has scheduled the release of its 2025 final results for March 5, 2026. The announcement will be made at 6:00 am EST, 11:00 am GMT and 7:00 pm HKT, giving investors in major markets simultaneous access.
Management will host two webcast presentations for analysts and investors to review the results and take questions. An English webcast is set for 8:00 am EST on March 5, 2026, and a Putonghua webcast for the Hong Kong and mainland China audience will follow on March 6, 2026. Live and replay access will be available via the company’s website.
Positive
- None.
Negative
- None.
FAQ
When will HUTCHMED (HCM) announce its 2025 final results?
HUTCHMED will announce its 2025 final results on Thursday, March 5, 2026. The release is scheduled for 6:00 am EST, which corresponds to 11:00 am GMT and 7:00 pm Hong Kong Time, allowing broad global investor access to the information simultaneously.
What investor webcasts is HUTCHMED (HCM) hosting for the 2025 results?
HUTCHMED will host two investor webcasts to discuss its 2025 final results. The English webcast is on March 5, 2026 at 8:00 am EST, while the Putonghua webcast is on March 6, 2026 at 8:30 am HKT, each followed by Q&A sessions.
How can investors access HUTCHMED (HCM) 2025 results webcasts and replays?
Investors can access HUTCHMED’s 2025 results webcasts live via the company website at www.hutch-med.com/event/. The presentation slides will be available shortly before each webcast, and replay recordings will be posted on the same site shortly after the events conclude.
In which languages will HUTCHMED (HCM) present its 2025 final results?
HUTCHMED will present its 2025 final results in both English and Putonghua. The English webcast targets global investors, while the Putonghua session focuses on Greater China audiences, offering language-appropriate presentations and Q&A opportunities for each investor group.
What type of company is HUTCHMED (HCM) according to this disclosure?
HUTCHMED is described as an innovative, commercial-stage biopharmaceutical company. It focuses on discovering, developing, and commercializing targeted therapies and immunotherapies for cancer and immunological diseases, with three medicines already marketed in China and one approved in major global markets.
Where is HUTCHMED (HCM) primarily based and listed?
HUTCHMED’s principal executive offices are in Hong Kong, and the company highlights its presence in Hong Kong, Shanghai and Florham Park, New Jersey. It is listed on Nasdaq and the Hong Kong Stock Exchange, reflecting both U.S. and Hong Kong capital market access.
